| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.005 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.096 | 0.005 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.006 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.14 | 0.007 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.09 | 0.007 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.007 |